Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 15/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14667121 | 1.00 | SYK (0.55) | SYKMAPK8JAK2JAK1JAK3 | |
| SCHEMBL14658160 | 1.00 | SYK (0.55) | SYKMAPK8JAK2JAK1JAK3 | |
| SCHEMBL14657604 | 1.00 | SYK (0.55) | SYKMAPK8JAK2JAK1JAK3 | |
| SCHEMBL14671024 | 1.00 | SYK (0.55) | SYKMAPK8JAK2JAK1JAK3 | |
| SCHEMBL14657608 | 1.00 | SYK (0.55) | SYKMAPK8JAK2JAK1JAK3 | |
| SCHEMBL14657601 | 1.00 | SYK (0.55) | SYKMAPK8JAK2JAK1JAK3 | |
| SCHEMBL14667120 | 1.00 | SYK (0.55) | SYKMAPK8JAK2JAK1JAK3 | |
| SCHEMBL14658163 | 1.00 | SYK (0.55) | SYKMAPK8JAK2JAK1JAK3 | |
| SCHEMBL14657534 | 0.95 | SYK (0.60) | SYKMAPK8JAK2JAK1JAK3 | |
| SCHEMBL14658039 | 0.95 | SYK (0.60) | SYKMAPK8JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328223-A2 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-2699553-B1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230116093-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-04-13 | — | — | US | disclosed |
| US-11325890-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210114992-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2021-04-22 | — | — | US | disclosed |
| US-10919865-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190194144-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2019-06-27 | — | — | US | disclosed |
| US-10266500-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180305322-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2018-10-25 | — | — | US | disclosed |
| US-10040770-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170267647-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2017-09-21 | — | — | US | disclosed |
| US-9701643-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150336901-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-11-26 | — | — | US | disclosed |
| US-9139534-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130029987-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029987-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | SYK 2460/4885MAPK8 45/4885JAK2 76/4885 |
| US-20230116093-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | SYK 2460/4885MAPK8 45/4885JAK2 76/4885 |
| US-20150336901-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | SYK 2460/4885MAPK8 45/4885JAK2 76/4885 |
| US-20210114992-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | SYK 2460/4885MAPK8 45/4885JAK2 76/4885 |
| US-20190194144-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | SYK 2460/4885MAPK8 45/4885JAK2 76/4885 |
| US-10040770-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | SYK 2460/4885MAPK8 45/4885JAK2 76/4885 |
| US-20180305322-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | SYK 2460/4885MAPK8 45/4885JAK2 76/4885 |
| US-10266500-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | SYK 2460/4885MAPK8 45/4885JAK2 76/4885 |
| US-11325890-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | SYK 2460/4885MAPK8 45/4885JAK2 76/4885 |
| US-20170267647-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | SYK 2460/4885MAPK8 45/4885JAK2 76/4885 |
| US-10919865-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | SYK 2460/4885MAPK8 45/4885JAK2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.